Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia

Abstract

Since last December, the outbreak of 2019-nCoV in Wuhan has caused ever-increasing attention and public panic all over the world. Up to February 9, 2020, 40,171 patients had been diagnosed with 2019-nCoV infection, including 6484 (16.14%) severe cases and 908 deaths (2.27%). Compared to SARS and MERS, 2019-nCoV appears to be much more contagious but less lethal, as most patients have mild symptoms and good prognosis 1 , 2 . However, according to the Chinese government’s daily report, 13.2–21.3% of patients with 2019-nCoV infection developed into severe or fatal illness (Fig. S1a ), which is characterized by the rapid development to acute respiratory distress syndrome (ARDS) or septic shock. Along with an increasing number of confirmed cases, the cumulative total of severe patients with 2019-nCoV is growing (Fig. S1b ). Treatment of these critically ill patients is becoming one of the major challenges we are facing.

References 17

1. 1.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

2. 2.
   SARS: Systematic Review of Treatment Effects · 2006

   No notice
3. 3.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

4. 4.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

5. 5.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

6. 6.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

7. 7.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

8. 8.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

9. 9.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

10. 10.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

11. 11.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

12. 12.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

13. 13.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

14. 14.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

15. 15.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

16. 16.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

17. 17.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

Cited by papers we hold 8

• Cytokine Storm: The Primary Determinant for the Pathophysiological Evolution of COVID-19 Deterioration · 2021
  No notice
• COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs · 2020
  No notice
• Flattening the COVID-19 Curve With Natural Killer Cell Based Immunotherapies · 2020
  No notice
• Repurposing existing drugs for COVID-19: an endocrinology perspective · 2020
  Not checked
• Diagnostic and prognostic value of hematological and immunological markers in COVID-19 infection: A meta-analysis of 6320 patients · 2020
  No notice
• A retrospective cohort study of methylprednisolone therapy in severe patients with COVID-19 pneumonia · 2020
  No notice
• Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies · 2020
  No notice
• Use of Corticosteroids in Coronavirus Disease 2019 Pneumonia: A Systematic Review of the Literature · 2020
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.